Volume 30, Number 6—June 2024
Synopsis
Severe Human Parainfluenza Virus Community- and Healthcare-Acquired Pneumonia in Adults at Tertiary Hospital, Seoul, South Korea, 2010–2019
Table 3
Patient outcomes | HPIV infections |
Influenza virus infections |
p value† | |||||
---|---|---|---|---|---|---|---|---|
Total, n = 143 | CAP, n = 80 | HAP, n = 63 | Total, n = 189 | CAP, n = 133 | HAP, n = 56 | |||
Mortality rates | ||||||||
7 d | 20 (14.0) | 8 (10.0) | 12 (19.0) | 16/185 (8.6) | 11/132 (8.3) | 5/53 (9.4) | 0.13 | |
30 d | 57 (39.9) | 22 (27.5) | 35 (55.6) | 61/185 (33.0) | 41/132 (31.1) | 20/53 (37.7) | 0.21 | |
60 d | 73 (51.0) | 30 (37.5) | 43 (68.3) | 81/185 (43.8) | 50/132 (37.9) | 31/53 (58.5) | 0.21 | |
90 d | 79 (55.2) | 34 (42.5) | 45 (71.4) | 89/185 (48.1) | 53/132 (40.2) | 36/53 (67.9) | 0.22 | |
In-hospital |
73 (51.0) |
29 (36.3) |
44 (69.8) |
78/185 (42.2) |
46/132 (34.8) |
32/53 (60.4) |
0.10 |
|
Mean ICU stay, d (+SD) | 17.1 (+19.4) | 17.4 (+23.0) | 16.7 (+13.7) | 17.6 (+17.3) | NA | NA | 0.82 | |
Mean hospital stay, d (+SD) ‡ |
50.1 (+47.4) |
39.5 (+40.5) |
63.6 (+52.2) |
53.1 (+71.4) |
NA |
NA |
0.66 |
|
Ventilator-associated pneumonia | 15 (10.5) | 4 (5.0) | 11 (17.5) | 25 (13.3) | 15 (11.3) | 10 (17.9) | 0.44 |
*Values are no. (%) except as indicated. Denominators are different in some cases because of missing data. CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; HPIV, human parainfluenza virus; ICU, intensive care unit; IQR, interquartile range; NA, not applicable. †p values were calculated by comparing total numbers of severe HPIV-associated pneumonia and severe influenza virus-associated pneumonia. ‡Defined as the period from hospital admission to discharge from the hospital or death.
1These authors contributed equally to this article.
Page created: April 19, 2024
Page updated: May 22, 2024
Page reviewed: May 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.